Daily dietary supplement.

The recommended daily dose contains:

  • 850 mg of omega-3
  • 650 mg of EPA
  • 100 mg of DHA

Supercritical Concentration (SCC): a technology that provides fish oil with a high degree of purity and high concentrations for EPA and DHA. An environmentally friendly technology that uses a low temperature extraction process to avoid harming the essential fatty acids.

Om3gafortSCC EPA Premium/FDC uses rigid LiqFillCapsTM capsules that facilitate better EPA absorption by the body.

NUTRITIONAL VALUES

Directions for use: Take 2 capsules a day during meals.

Amount per capsule % DV*
Energy value 10 kcal=42 kJ 0
Total fats 1 g, of which: 2
saturated fats 0 g 0
trans fats 0 g
monounsaturated fats 0 g
polyunsaturated fats 1,0 g, of which
     eicosapentaenoic acid (EPA) 650 mg
     docosahexaenoic acids (DHA) 100 mg
Cholesterol 20 mg
Vitamin E 2 mg 20

Does not contain significant amounts of carbohydrates, proteins, dietary fibre or sodium.

*Daily values based on a diet of 2,000 kcal or 8,400 kJ. Your daily values may be higher or lower depending on your energy requirements.

INGREDIENTS:

Fish oil, D-alpha tocoferol, sunflower oil, emulsifier, soy lecithin and capsules (gelatine and gelling agent, red colouring 40).

.

Cardiovascular protection:
  1. Chan EJ, Cho L. What can we expect from omega-3 fatty acids? Cleve Clin J Med. 2009 Apr;76(4):245-51.
High blood pressure (Hypertension):
  1. Grynberg A. Hypertension prevention: from nutrients to (fortified) foods to dietary patterns. Focus on fatty acids. J Hum Hypertens. 2005 Dec;19 Suppl 3:S25-33.
Triglycerides and HDL
  1. von Schacky C. A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels. Vasc Health Risk Manag. 2006;2(3):251-62.

el contenido de esta página requiere una versión más reciente de adobe flash player.

Obtener adobe flash player

LiqFillCapsTM are an innovative technological concept that provides an efficient solution to the many challenges the pharmaceutical and nutraceutical industries face, in particular those due to the low solubility of active ingredients and bioactive agents, thereby helping to achieve an increase in both oral bioavailability and absorption.